Organic Sonosensitizers-based SDT with enhanced ROS generation.

IF 9.7 1区化学 Q1 ACOUSTICS

Ultrasonics Sonochemistry Pub Date : 2025-10-15 DOI:10.1016/j.ultsonch.2025.107625

Qianyun Shan, Rumei Li, Bin Ying, Wei Zhu, Xiaojin Wu, Shouxing Xu, Xuanxuan Zhang, Zhikang Xu, Xinyue Zhu, Weiyu Chen, Kai Zhang, Jian Chen

{"title":"Organic Sonosensitizers-based SDT with enhanced ROS generation.","authors":"Qianyun Shan, Rumei Li, Bin Ying, Wei Zhu, Xiaojin Wu, Shouxing Xu, Xuanxuan Zhang, Zhikang Xu, Xinyue Zhu, Weiyu Chen, Kai Zhang, Jian Chen","doi":"10.1016/j.ultsonch.2025.107625","DOIUrl":null,"url":null,"abstract":"Organic sonosensitizer-based sonodynamic therapy (SDT) is an emerging, non-invasive strategy for cancer treatment, leveraging ultrasound (US) activation to trigger reactive oxygen species (ROS) production and induce tumor cell apoptosis. However, the clinical translation of SDT is limited by two key factors: the intrinsically low ROS quantum yield of many organic sonosensitizers and the hypoxic tumor microenvironment (TME), which restricts O2-dependent ROS generation. This review systematically examines recent molecular design strategies aimed at enhancing ROS production, including heavy atom incorporation, donor-acceptor (D-A) architecture design, π-conjugation extension, and solubility modulation. Furthermore, we evaluated innovative O2-delivery/generation tumor reoxygenation approaches for enhanced SDT, such as O2-nanocarriers, in-situ catalytic O2 generation, and mitochondrial respiration modulation etc. Notably, integrating clinically validated sonosensitizers like porphyrins with translational O2-delivery systems such as perfluorocarbon (PFC) nanoemulsions or vascular normalization, offers a synergistic strategy to overcome tumor hypoxia, amplify ROS generation, and unlock the full therapeutic potential of SDT in future clinical applications.","PeriodicalId":442,"journal":{"name":"Ultrasonics Sonochemistry","volume":"122 ","pages":"107625"},"PeriodicalIF":9.7000,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ultrasonics Sonochemistry","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1016/j.ultsonch.2025.107625","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ACOUSTICS","Score":null,"Total":0}

引用次数: 0

Abstract

Organic sonosensitizer-based sonodynamic therapy (SDT) is an emerging, non-invasive strategy for cancer treatment, leveraging ultrasound (US) activation to trigger reactive oxygen species (ROS) production and induce tumor cell apoptosis. However, the clinical translation of SDT is limited by two key factors: the intrinsically low ROS quantum yield of many organic sonosensitizers and the hypoxic tumor microenvironment (TME), which restricts O₂-dependent ROS generation. This review systematically examines recent molecular design strategies aimed at enhancing ROS production, including heavy atom incorporation, donor-acceptor (D-A) architecture design, π-conjugation extension, and solubility modulation. Furthermore, we evaluated innovative O₂-delivery/generation tumor reoxygenation approaches for enhanced SDT, such as O₂-nanocarriers, in-situ catalytic O₂ generation, and mitochondrial respiration modulation etc. Notably, integrating clinically validated sonosensitizers like porphyrins with translational O₂-delivery systems such as perfluorocarbon (PFC) nanoemulsions or vascular normalization, offers a synergistic strategy to overcome tumor hypoxia, amplify ROS generation, and unlock the full therapeutic potential of SDT in future clinical applications.

查看原文本刊更多论文

基于有机声敏剂的SDT与增强ROS生成。

基于有机声敏剂的声动力疗法（SDT）是一种新兴的、无创的癌症治疗策略，利用超声（US）激活来触发活性氧（ROS）的产生并诱导肿瘤细胞凋亡。然而，SDT的临床翻译受到两个关键因素的限制：许多有机声敏剂固有的低ROS量子产率和低氧肿瘤微环境（TME），这限制了o2依赖性ROS的产生。这篇综述系统地研究了最近的分子设计策略，旨在提高ROS的产生，包括重原子掺入，供体-受体（D-A）结构设计，π共轭扩展和溶解度调节。此外，我们评估了用于增强SDT的创新的O2递送/生成肿瘤再氧化方法，如O2纳米载体、原位催化O2生成和线粒体呼吸调节等。值得注意的是，将临床验证的超声增敏剂（如卟啉）与平移o2递送系统（如全氟碳纳米乳）或血管正常化相结合，提供了一种协同策略，以克服肿瘤缺氧，放大ROS的产生，并在未来的临床应用中释放SDT的全部治疗潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ultrasonics Sonochemistry 化学-化学综合

CiteScore

15.80

自引率

11.90%

发文量

361

审稿时长

59 days

期刊介绍： Ultrasonics Sonochemistry stands as a premier international journal dedicated to the publication of high-quality research articles primarily focusing on chemical reactions and reactors induced by ultrasonic waves, known as sonochemistry. Beyond chemical reactions, the journal also welcomes contributions related to cavitation-induced events and processing, including sonoluminescence, and the transformation of materials on chemical, physical, and biological levels. Since its inception in 1994, Ultrasonics Sonochemistry has consistently maintained a top ranking in the "Acoustics" category, reflecting its esteemed reputation in the field. The journal publishes exceptional papers covering various areas of ultrasonics and sonochemistry. Its contributions are highly regarded by both academia and industry stakeholders, demonstrating its relevance and impact in advancing research and innovation.